Multiple Sclerosis Drug Market Size & Share, by Drug (Immunomodulators, Immunosuppressants, Interferons); Medication Type (Oral, Injection); Type (Clinically Isolated Syndrome, Relapse-Remitting MS, Primary Progressive MS, Secondary Progressive MS); Treatment (Medications, Stem Cell Therapy, Physical Therapy, Plasma Exchange); End-user (Hospitals, Specialty, Clinics, Homecare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 1986
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Companies Dominating the Multiple Sclerosis Drug Landscape

top-features-companies
    • Biogen
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Merck KGaA.
    • Janssen Pharmaceuticals Companies of Johnson & Johnson
    • Bristol-Myers Squibb Company
    • Cipla Inc. 

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Janssen Pharmaceutical Companies announced the approval of PONVORY by the U.S. Food and Drug Administration. Ponvory is an oral medication used for treating adults with relapsing multiple Sclerosis.
  • Biogen collaborated with Eisai Co., Ltd., for the co-promotion of multiple sclerosis treatments including Tecfidera, Tysabri, and Avonex in Japan.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 1986
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Factors such as, higher prevalence of multiple sclerosis, advancement in research and development, higher instances of women having multiple sclerosis and government efforts for the treatment is to drive the market growth.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023-2033.

High cost of treatment of multiple sclerosis, shortage of skilled professionals and challenges to develop the drugs for the treatment are few factors which are to hamper the market growth.

The major players in the market are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Merck KGaA., Janssen Pharmaceuticals Companies of Johnson & Johnson, Bristol-Myers Squibb Company, Cipla Inc., and so on…

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug, type, medication type, treatment, end user, and by region.

The oral segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying